Synapse Open Synapse
Biology

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

GEN · · 7 min read

Sanofi halted development of an oral STAT6 degrader that had been under study in a Phase I first-in-human trial in Europe. STAT6, a key drug target in type 2 inflammation, is among the five targets identified by the companies in their collaboration, launched in 2020.

Latest from GEN